ACLARIS THERAPEUTICS INC

Topical Drug Delivery Market Set to Reach $454.93 Billion by 2031 as Targeted Delivery Technologies Advance

3 months ago

• The global topical drug delivery market is projected to grow from $226.31 billion in 2023 to $454.93 billion by 2031, representing a CAGR of 9.1%, driven by increasing demand for non-invasive treatment options. • Targeted drug delivery devices market is expected to grow at a faster CAGR of 19.7% through 2035, with intratumoral delivery dominating the segment and immunotherapy applications leading current market share. • Technological advancements in drug delivery systems are enabling more precise administration to specific organs, with devices targeting the brain showing promising growth potential despite breast-targeted devices currently driving overall market volume.

Arvinas Advances Vepdegestrant into Phase 3 Trials for Breast Cancer and Updates Pipeline Milestones

4 months ago

• Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor. • Topline data from the Phase 3 VERITAC-2 monotherapy trial of vepdegestrant in second-line-plus ER+/HER2- metastatic breast cancer is anticipated in the first quarter of 2025. • Arvinas is set to present initial data from the Phase 1 trial of ARV-393 in B-cell lymphomas and file an IND application for a novel PROTAC KRAS G12D degrader in 2025. • Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease has been initiated, with data expected to be presented in the first half of 2025.